Custom Search

News

Wednesday 01 February 2006

Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient.

By: Saigo K, Okumachi Y, Kondo S, Chinzei T, Okamura A, Takenokuchi M, Kawano S, Kumagai S.

Leuk Lymphoma 2006 Feb;47(2):353-6

A 48-year-old male patient with follicular lymphoma, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission. After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with etoposide, sobuzoxane or methotrexate, only resulted in a stable disease response. However, the fourth course of rituximab combined with a small dose of melphalan produced excellent results and the complete response continued for more than 15 months. It is possible that these two drugs may act synergistically.

Use of this site is subject to the following terms of use